DURAGESIC-100
LOE ApproachingNDATRANSDERMALFILM, EXTENDED RELEASE
Approved
Aug 1990
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Data completeness
1/8 — Limited
Drug data last refreshed 2d ago · AI intelligence enriched 2w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
DURAGESIC-100 is a transdermal extended-release film formulation approved in 1990 for chronic pain management. The product delivers medication through the skin over an extended period, providing sustained analgesia for opioid-tolerant patients. Generic name and mechanism are not publicly documented in this data set.
LOE Approaching
Product is approaching loss of exclusivity with moderate competitive pressure (30), signaling potential team restructuring and shift toward generic defense or portfolio transition.
Mechanism of Action
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Career Relevance
Working on DURAGESIC-100 positions you in a mature product defense and market access context with minimal linked job openings. Career growth depends on driving generic mitigation strategies, patient retention, and portfolio transition planning within J&J's pain management franchise.
Brand ManagerField Sales Representative
Worked on DURAGESIC-100 at Johnson & Johnson? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.